American Society of Hematology

Fig. 5.

$Fig. 5. MplY582F has a proliferative advantage over wild-type Mpl. / (A) Growth curves of unfractionatedGPIIb-tva+mpl−/− bone marrow grown in TPO-containing media after infection with RCAS-Mpl, RCAS-MplY582F, RCAS-MplΔ50, or RCAS-GFP. (B) Plating equal numbers of TPO-responsiveGPIIb-tva+mpl−/− bone marrow cells expressing wild-type Mpl, MplY582F, or MplΔ50 demonstrates a clear proliferative advantage imparted by the Y582F mutation. (C) Percentage of apoptotic cells at various h-TPO concentrations was determined for cells expressing Mpl, MplY582F, and MplΔ50. The percentage of apoptotic cells includes all cells that stain with FITC-conjugated anti-annexin V antibody, annexin V+/PI− and annexin V+/PI+ cells. Results are the average and standard deviation of 3 to 5 independent experiments for each Mpl construct.$

MplY582F has a proliferative advantage over wild-type Mpl.

(A) Growth curves of unfractionatedGPIIb-tva⁺mpl^−/−bone marrow grown in TPO-containing media after infection with RCAS-Mpl, RCAS-MplY582F, RCAS-MplΔ50, or RCAS-GFP. (B) Plating equal numbers of TPO-responsiveGPIIb-tva⁺mpl^−/−bone marrow cells expressing wild-type Mpl, MplY582F, or MplΔ50 demonstrates a clear proliferative advantage imparted by the Y582F mutation. (C) Percentage of apoptotic cells at various h-TPO concentrations was determined for cells expressing Mpl, MplY582F, and MplΔ50. The percentage of apoptotic cells includes all cells that stain with FITC-conjugated anti-annexin V antibody, annexin V⁺/PI⁻ and annexin V⁺/PI⁺ cells. Results are the average and standard deviation of 3 to 5 independent experiments for each Mpl construct.

This Feature Is Available To Subscribers Only